Lausanne-based Hedera Dx, a BioTech company, today announced the closing of a €15 million Series A financing round to drive advanced cancer care and overcome structural barriers that prevent cancer patients from accessing targeted cancer therapies.
The round was led by Vsquared Ventures, with Tesi also joining as a new investor alongside participation from existing backers Helsana HealthInvest, Eyrir Venture Management, Inventure, and Top Harvest.
“At Hedera, we are building the infrastructure to make precision cancer care accessible to every patient and clinician – globally,” said Tommi Lehtonen, CEO and Co-founder of Hedera Dx. “While there is a large number of personalised cancer treatments on the market, a very large part of patient s still can’t access them. Our solutions empower hospital labs to perform sophisticated molecular diagnostics locally and cost efficiently.”
Founded in 2021, Hedera Dx is a BioTech company dedicated to removing barriers to precision medicine in oncology. The company’s integrated platform combines advanced molecular diagnostics with clinical data to inform treatment decisions and accelerate drug development.
Hedera’s team of 20+ professionals brings together expertise in genomics, clinical oncology, bioinformatics, artificial intelligence, and digital health.
Dr Lise Rechsteiner, General Partner at Vsquared Ventures, said: “Hedera Dx is addressing a critical gap in global oncology care. Hedera’s approach tackles the specific challenges of hospital in – house testing and results in more patients getting tested and more patients having access to targeted therapies . Hedera Dx’s combination of diagnostics and powerful real-world data capabilities positions them to become the definitive leader in precision oncology within health care systems outside the US.”
Hedera Dx has developed blood-based cancer testing solutions, known as liquid biopsies, to allow for cost efficient and easy to adopt in-house testing of cancer patients. The solution combines affordability with unprecedented quality and is already deployed across 11 European countries.
In addition to advanced molecular profiling of cancer patients that provides physicians with insights for treatment decisions, the AI-native platform also reportedly uncovers patient-centric from real-world data to support the development of next generation oncology treatments.
“We’re not only improving access to advanced cancer care for patients – we are creating an entirely new platform for real-world insights, driving access to life-saving precision oncology treatments and fuelling the next wave of innovative cancer therapies,” added Dr Christian Meisel, CMO and Co-founder of Hedera Dx.
The Series A funding will support continued commercial expansion and further development of the company’s real-world data infrastructure, addressing the vast global oncology market.
Read the orginal article: https://www.eu-startups.com/2025/05/swiss-biotech-hedera-dx-has-just-bagged-e15-million-to-bring-modern-cancer-care-to-patients-across-the-globe/
